nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCC1—Mitoxantrone—lymphatic system cancer	0.147	0.169	CbGbCtD
Vemurafenib—ABCG2—Teniposide—lymphatic system cancer	0.14	0.162	CbGbCtD
Vemurafenib—ABCC1—Vincristine—lymphatic system cancer	0.101	0.116	CbGbCtD
Vemurafenib—ABCG2—Mitoxantrone—lymphatic system cancer	0.0982	0.113	CbGbCtD
Vemurafenib—CYP1A2—Carmustine—lymphatic system cancer	0.0862	0.0993	CbGbCtD
Vemurafenib—ABCG2—Vincristine—lymphatic system cancer	0.0676	0.0779	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—lymphatic system cancer	0.0612	0.0705	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—lymphatic system cancer	0.0409	0.0472	CbGbCtD
Vemurafenib—CYP3A4—Cytarabine—lymphatic system cancer	0.0308	0.0355	CbGbCtD
Vemurafenib—CYP3A4—Teniposide—lymphatic system cancer	0.0303	0.035	CbGbCtD
Vemurafenib—ALB—Methotrexate—lymphatic system cancer	0.0282	0.0325	CbGbCtD
Vemurafenib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0212	0.0245	CbGbCtD
Vemurafenib—CYP3A4—Vincristine—lymphatic system cancer	0.0146	0.0168	CbGbCtD
Vemurafenib—Hyperkeratosis—Bleomycin—lymphatic system cancer	0.0053	0.04	CcSEcCtD
Vemurafenib—VIIth nerve paralysis—Carmustine—lymphatic system cancer	0.00322	0.0243	CcSEcCtD
Vemurafenib—VIIth nerve paralysis—Vincristine—lymphatic system cancer	0.00308	0.0232	CcSEcCtD
Vemurafenib—Neoplasm—Teniposide—lymphatic system cancer	0.00212	0.0161	CcSEcCtD
Vemurafenib—Sunburn—Methotrexate—lymphatic system cancer	0.00203	0.0153	CcSEcCtD
Vemurafenib—Cyst—Carmustine—lymphatic system cancer	0.00198	0.0149	CcSEcCtD
Vemurafenib—Paralysis—Vincristine—lymphatic system cancer	0.00182	0.0137	CcSEcCtD
Vemurafenib—Hepatotoxicity—Carmustine—lymphatic system cancer	0.00171	0.0129	CcSEcCtD
Vemurafenib—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00151	0.0114	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Mitoxantrone—lymphatic system cancer	0.00149	0.0113	CcSEcCtD
Vemurafenib—Alopecia—Mechlorethamine—lymphatic system cancer	0.00141	0.0107	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00135	0.0102	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00129	0.00973	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Vincristine—lymphatic system cancer	0.00128	0.00965	CcSEcCtD
Vemurafenib—Neoplasm—Carmustine—lymphatic system cancer	0.00119	0.00903	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00118	0.0089	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00115	0.00865	CcSEcCtD
Vemurafenib—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00114	0.00859	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00113	0.00856	CcSEcCtD
Vemurafenib—Arthritis—Bleomycin—lymphatic system cancer	0.00113	0.00854	CcSEcCtD
Vemurafenib—Infection—Mechlorethamine—lymphatic system cancer	0.00113	0.00854	CcSEcCtD
Vemurafenib—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0011	0.00835	CcSEcCtD
Vemurafenib—Chills—Teniposide—lymphatic system cancer	0.00106	0.008	CcSEcCtD
Vemurafenib—Alopecia—Teniposide—lymphatic system cancer	0.00104	0.00788	CcSEcCtD
Vemurafenib—Polyp—Methotrexate—lymphatic system cancer	0.00101	0.0076	CcSEcCtD
Vemurafenib—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.000988	0.00747	CcSEcCtD
Vemurafenib—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00098	0.00741	CcSEcCtD
Vemurafenib—Folliculitis—Methotrexate—lymphatic system cancer	0.000974	0.00736	CcSEcCtD
Vemurafenib—Chills—Fludarabine—lymphatic system cancer	0.00093	0.00703	CcSEcCtD
Vemurafenib—Alopecia—Fludarabine—lymphatic system cancer	0.000916	0.00692	CcSEcCtD
Vemurafenib—Pain in extremity—Vincristine—lymphatic system cancer	0.000916	0.00692	CcSEcCtD
Vemurafenib—Cyst—Methotrexate—lymphatic system cancer	0.000916	0.00692	CcSEcCtD
Vemurafenib—Malnutrition—Fludarabine—lymphatic system cancer	0.000903	0.00682	CcSEcCtD
Vemurafenib—Paralysis—Methotrexate—lymphatic system cancer	0.000881	0.00666	CcSEcCtD
Vemurafenib—Weight decreased—Bleomycin—lymphatic system cancer	0.000859	0.00649	CcSEcCtD
Vemurafenib—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000838	0.00633	CcSEcCtD
Vemurafenib—Infection—Teniposide—lymphatic system cancer	0.000833	0.00629	CcSEcCtD
Vemurafenib—Pruritus—Mechlorethamine—lymphatic system cancer	0.000804	0.00608	CcSEcCtD
Vemurafenib—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.000793	0.00599	CcSEcCtD
Vemurafenib—Cough—Fludarabine—lymphatic system cancer	0.000788	0.00595	CcSEcCtD
Vemurafenib—Hypotension—Teniposide—lymphatic system cancer	0.000783	0.00592	CcSEcCtD
Vemurafenib—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000778	0.00588	CcSEcCtD
Vemurafenib—Arthralgia—Fludarabine—lymphatic system cancer	0.000769	0.00581	CcSEcCtD
Vemurafenib—Myalgia—Fludarabine—lymphatic system cancer	0.000769	0.00581	CcSEcCtD
Vemurafenib—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000737	0.00557	CcSEcCtD
Vemurafenib—Infection—Fludarabine—lymphatic system cancer	0.000732	0.00553	CcSEcCtD
Vemurafenib—Decreased appetite—Teniposide—lymphatic system cancer	0.000729	0.00551	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000725	0.00548	CcSEcCtD
Vemurafenib—Vomiting—Mechlorethamine—lymphatic system cancer	0.000723	0.00546	CcSEcCtD
Vemurafenib—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000722	0.00546	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.000722	0.00546	CcSEcCtD
Vemurafenib—Rash—Mechlorethamine—lymphatic system cancer	0.000717	0.00542	CcSEcCtD
Vemurafenib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000716	0.00541	CcSEcCtD
Vemurafenib—Weight decreased—Vincristine—lymphatic system cancer	0.000716	0.00541	CcSEcCtD
Vemurafenib—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000697	0.00527	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000692	0.00523	CcSEcCtD
Vemurafenib—Chills—Bleomycin—lymphatic system cancer	0.000682	0.00515	CcSEcCtD
Vemurafenib—Nausea—Mechlorethamine—lymphatic system cancer	0.000675	0.0051	CcSEcCtD
Vemurafenib—Alopecia—Bleomycin—lymphatic system cancer	0.000672	0.00508	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000671	0.00507	CcSEcCtD
Vemurafenib—Body temperature increased—Teniposide—lymphatic system cancer	0.000663	0.00501	CcSEcCtD
Vemurafenib—Erythema—Bleomycin—lymphatic system cancer	0.000662	0.005	CcSEcCtD
Vemurafenib—Oedema peripheral—Carmustine—lymphatic system cancer	0.000654	0.00494	CcSEcCtD
Vemurafenib—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000652	0.00493	CcSEcCtD
Vemurafenib—Decreased appetite—Fludarabine—lymphatic system cancer	0.00064	0.00484	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000636	0.00481	CcSEcCtD
Vemurafenib—Fatigue—Fludarabine—lymphatic system cancer	0.000635	0.0048	CcSEcCtD
Vemurafenib—Constipation—Fludarabine—lymphatic system cancer	0.00063	0.00476	CcSEcCtD
Vemurafenib—Vasculitis—Methotrexate—lymphatic system cancer	0.000627	0.00474	CcSEcCtD
Vemurafenib—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000623	0.0047	CcSEcCtD
Vemurafenib—Eye disorder—Carmustine—lymphatic system cancer	0.00062	0.00469	CcSEcCtD
Vemurafenib—Hypersensitivity—Teniposide—lymphatic system cancer	0.000618	0.00467	CcSEcCtD
Vemurafenib—Asthenia—Teniposide—lymphatic system cancer	0.000601	0.00454	CcSEcCtD
Vemurafenib—Pruritus—Teniposide—lymphatic system cancer	0.000593	0.00448	CcSEcCtD
Vemurafenib—Cardiac disorder—Vincristine—lymphatic system cancer	0.000588	0.00444	CcSEcCtD
Vemurafenib—Alopecia—Carmustine—lymphatic system cancer	0.000586	0.00443	CcSEcCtD
Vemurafenib—Body temperature increased—Fludarabine—lymphatic system cancer	0.000582	0.0044	CcSEcCtD
Vemurafenib—Erythema—Carmustine—lymphatic system cancer	0.000578	0.00437	CcSEcCtD
Vemurafenib—Malnutrition—Carmustine—lymphatic system cancer	0.000578	0.00437	CcSEcCtD
Vemurafenib—Cough—Bleomycin—lymphatic system cancer	0.000578	0.00436	CcSEcCtD
Vemurafenib—Angiopathy—Vincristine—lymphatic system cancer	0.000575	0.00434	CcSEcCtD
Vemurafenib—Diarrhoea—Teniposide—lymphatic system cancer	0.000574	0.00433	CcSEcCtD
Vemurafenib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000571	0.00431	CcSEcCtD
Vemurafenib—Myalgia—Bleomycin—lymphatic system cancer	0.000563	0.00426	CcSEcCtD
Vemurafenib—Alopecia—Vincristine—lymphatic system cancer	0.00056	0.00423	CcSEcCtD
Vemurafenib—Back pain—Carmustine—lymphatic system cancer	0.000559	0.00422	CcSEcCtD
Vemurafenib—Chills—Mitoxantrone—lymphatic system cancer	0.000554	0.00418	CcSEcCtD
Vemurafenib—Neoplasm—Methotrexate—lymphatic system cancer	0.000553	0.00418	CcSEcCtD
Vemurafenib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000545	0.00412	CcSEcCtD
Vemurafenib—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000543	0.0041	CcSEcCtD
Vemurafenib—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00054	0.00408	CcSEcCtD
Vemurafenib—Erythema—Mitoxantrone—lymphatic system cancer	0.000537	0.00406	CcSEcCtD
Vemurafenib—Infection—Bleomycin—lymphatic system cancer	0.000537	0.00405	CcSEcCtD
Vemurafenib—Back pain—Vincristine—lymphatic system cancer	0.000533	0.00403	CcSEcCtD
Vemurafenib—Vomiting—Teniposide—lymphatic system cancer	0.000533	0.00403	CcSEcCtD
Vemurafenib—Asthenia—Fludarabine—lymphatic system cancer	0.000529	0.00399	CcSEcCtD
Vemurafenib—Rash—Teniposide—lymphatic system cancer	0.000529	0.00399	CcSEcCtD
Vemurafenib—Dermatitis—Teniposide—lymphatic system cancer	0.000528	0.00399	CcSEcCtD
Vemurafenib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000526	0.00397	CcSEcCtD
Vemurafenib—Headache—Teniposide—lymphatic system cancer	0.000525	0.00397	CcSEcCtD
Vemurafenib—Pruritus—Fludarabine—lymphatic system cancer	0.000521	0.00394	CcSEcCtD
Vemurafenib—Back pain—Mitoxantrone—lymphatic system cancer	0.00052	0.00393	CcSEcCtD
Vemurafenib—Photosensitivity—Methotrexate—lymphatic system cancer	0.000506	0.00382	CcSEcCtD
Vemurafenib—Hypotension—Bleomycin—lymphatic system cancer	0.000505	0.00381	CcSEcCtD
Vemurafenib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000504	0.00381	CcSEcCtD
Vemurafenib—Nausea—Teniposide—lymphatic system cancer	0.000498	0.00376	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000492	0.00372	CcSEcCtD
Vemurafenib—Myalgia—Carmustine—lymphatic system cancer	0.000492	0.00372	CcSEcCtD
Vemurafenib—Decreased appetite—Bleomycin—lymphatic system cancer	0.00047	0.00355	CcSEcCtD
Vemurafenib—Myalgia—Vincristine—lymphatic system cancer	0.00047	0.00355	CcSEcCtD
Vemurafenib—Cough—Mitoxantrone—lymphatic system cancer	0.000469	0.00354	CcSEcCtD
Vemurafenib—Infection—Carmustine—lymphatic system cancer	0.000468	0.00354	CcSEcCtD
Vemurafenib—Vomiting—Fludarabine—lymphatic system cancer	0.000468	0.00354	CcSEcCtD
Vemurafenib—Rash—Fludarabine—lymphatic system cancer	0.000465	0.00351	CcSEcCtD
Vemurafenib—Dermatitis—Fludarabine—lymphatic system cancer	0.000464	0.00351	CcSEcCtD
Vemurafenib—Headache—Fludarabine—lymphatic system cancer	0.000462	0.00349	CcSEcCtD
Vemurafenib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000457	0.00346	CcSEcCtD
Vemurafenib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000457	0.00346	CcSEcCtD
Vemurafenib—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00045	0.0034	CcSEcCtD
Vemurafenib—Infection—Vincristine—lymphatic system cancer	0.000447	0.00338	CcSEcCtD
Vemurafenib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000441	0.00334	CcSEcCtD
Vemurafenib—Hypotension—Carmustine—lymphatic system cancer	0.000441	0.00333	CcSEcCtD
Vemurafenib—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000438	0.00331	CcSEcCtD
Vemurafenib—Nausea—Fludarabine—lymphatic system cancer	0.000438	0.00331	CcSEcCtD
Vemurafenib—Infection—Mitoxantrone—lymphatic system cancer	0.000435	0.00329	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00043	0.00325	CcSEcCtD
Vemurafenib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000427	0.00323	CcSEcCtD
Vemurafenib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000426	0.00322	CcSEcCtD
Vemurafenib—Hypotension—Vincristine—lymphatic system cancer	0.000421	0.00318	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00041	0.0031	CcSEcCtD
Vemurafenib—Decreased appetite—Carmustine—lymphatic system cancer	0.00041	0.0031	CcSEcCtD
Vemurafenib—Hypotension—Mitoxantrone—lymphatic system cancer	0.00041	0.00309	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000407	0.00308	CcSEcCtD
Vemurafenib—Constipation—Carmustine—lymphatic system cancer	0.000403	0.00305	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.0004	0.00302	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000399	0.00302	CcSEcCtD
Vemurafenib—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000398	0.00301	CcSEcCtD
Vemurafenib—Decreased appetite—Vincristine—lymphatic system cancer	0.000391	0.00296	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000389	0.00294	CcSEcCtD
Vemurafenib—Fatigue—Vincristine—lymphatic system cancer	0.000388	0.00293	CcSEcCtD
Vemurafenib—Asthenia—Bleomycin—lymphatic system cancer	0.000388	0.00293	CcSEcCtD
Vemurafenib—Constipation—Vincristine—lymphatic system cancer	0.000385	0.00291	CcSEcCtD
Vemurafenib—Pruritus—Bleomycin—lymphatic system cancer	0.000382	0.00289	CcSEcCtD
Vemurafenib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000381	0.00288	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—lymphatic system cancer	0.00038	0.00287	CcSEcCtD
Vemurafenib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000378	0.00286	CcSEcCtD
Vemurafenib—Constipation—Mitoxantrone—lymphatic system cancer	0.000375	0.00283	CcSEcCtD
Vemurafenib—Body temperature increased—Carmustine—lymphatic system cancer	0.000373	0.00282	CcSEcCtD
Vemurafenib—Body temperature increased—Vincristine—lymphatic system cancer	0.000356	0.00269	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000351	0.00265	CcSEcCtD
Vemurafenib—Hypersensitivity—Carmustine—lymphatic system cancer	0.000347	0.00262	CcSEcCtD
Vemurafenib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000347	0.00262	CcSEcCtD
Vemurafenib—Vomiting—Bleomycin—lymphatic system cancer	0.000343	0.0026	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000342	0.00259	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—lymphatic system cancer	0.000342	0.00259	CcSEcCtD
Vemurafenib—Rash—Bleomycin—lymphatic system cancer	0.000341	0.00257	CcSEcCtD
Vemurafenib—Dermatitis—Bleomycin—lymphatic system cancer	0.00034	0.00257	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000339	0.00257	CcSEcCtD
Vemurafenib—Asthenia—Carmustine—lymphatic system cancer	0.000338	0.00256	CcSEcCtD
Vemurafenib—Hypersensitivity—Vincristine—lymphatic system cancer	0.000332	0.00251	CcSEcCtD
Vemurafenib—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000323	0.00244	CcSEcCtD
Vemurafenib—Asthenia—Vincristine—lymphatic system cancer	0.000323	0.00244	CcSEcCtD
Vemurafenib—Diarrhoea—Carmustine—lymphatic system cancer	0.000323	0.00244	CcSEcCtD
Vemurafenib—Nausea—Bleomycin—lymphatic system cancer	0.000321	0.00242	CcSEcCtD
Vemurafenib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000315	0.00238	CcSEcCtD
Vemurafenib—Dizziness—Carmustine—lymphatic system cancer	0.000312	0.00236	CcSEcCtD
Vemurafenib—Diarrhoea—Vincristine—lymphatic system cancer	0.000308	0.00233	CcSEcCtD
Vemurafenib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0003	0.00227	CcSEcCtD
Vemurafenib—Vomiting—Carmustine—lymphatic system cancer	0.0003	0.00227	CcSEcCtD
Vemurafenib—Dizziness—Vincristine—lymphatic system cancer	0.000298	0.00225	CcSEcCtD
Vemurafenib—Rash—Carmustine—lymphatic system cancer	0.000297	0.00225	CcSEcCtD
Vemurafenib—Dermatitis—Carmustine—lymphatic system cancer	0.000297	0.00224	CcSEcCtD
Vemurafenib—Headache—Carmustine—lymphatic system cancer	0.000295	0.00223	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000291	0.0022	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—lymphatic system cancer	0.000287	0.00217	CcSEcCtD
Vemurafenib—Vomiting—Vincristine—lymphatic system cancer	0.000286	0.00216	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000285	0.00216	CcSEcCtD
Vemurafenib—Rash—Vincristine—lymphatic system cancer	0.000284	0.00214	CcSEcCtD
Vemurafenib—Dermatitis—Vincristine—lymphatic system cancer	0.000284	0.00214	CcSEcCtD
Vemurafenib—Headache—Vincristine—lymphatic system cancer	0.000282	0.00213	CcSEcCtD
Vemurafenib—Nausea—Carmustine—lymphatic system cancer	0.00028	0.00212	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—lymphatic system cancer	0.000279	0.00211	CcSEcCtD
Vemurafenib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000279	0.00211	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000277	0.00209	CcSEcCtD
Vemurafenib—Rash—Mitoxantrone—lymphatic system cancer	0.000276	0.00209	CcSEcCtD
Vemurafenib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000276	0.00209	CcSEcCtD
Vemurafenib—Chills—Methotrexate—lymphatic system cancer	0.000276	0.00208	CcSEcCtD
Vemurafenib—Headache—Mitoxantrone—lymphatic system cancer	0.000275	0.00207	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—lymphatic system cancer	0.000272	0.00205	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—lymphatic system cancer	0.000268	0.00202	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—lymphatic system cancer	0.000268	0.00202	CcSEcCtD
Vemurafenib—Nausea—Vincristine—lymphatic system cancer	0.000267	0.00202	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000262	0.00198	CcSEcCtD
Vemurafenib—Nausea—Mitoxantrone—lymphatic system cancer	0.00026	0.00197	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—lymphatic system cancer	0.000259	0.00196	CcSEcCtD
Vemurafenib—Cough—Methotrexate—lymphatic system cancer	0.000234	0.00176	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—lymphatic system cancer	0.000228	0.00172	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—lymphatic system cancer	0.000228	0.00172	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000226	0.00171	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000218	0.00165	CcSEcCtD
Vemurafenib—Infection—Methotrexate—lymphatic system cancer	0.000217	0.00164	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000214	0.00162	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—lymphatic system cancer	0.000212	0.0016	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—lymphatic system cancer	0.000204	0.00154	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000199	0.0015	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—lymphatic system cancer	0.00019	0.00143	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000189	0.00142	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—lymphatic system cancer	0.000188	0.00142	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—lymphatic system cancer	0.000173	0.0013	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000161	0.00122	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—lymphatic system cancer	0.000157	0.00118	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—lymphatic system cancer	0.000155	0.00117	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—lymphatic system cancer	0.000149	0.00113	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—lymphatic system cancer	0.000144	0.00109	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—lymphatic system cancer	0.000139	0.00105	CcSEcCtD
Vemurafenib—Rash—Methotrexate—lymphatic system cancer	0.000138	0.00104	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—lymphatic system cancer	0.000138	0.00104	CcSEcCtD
Vemurafenib—Headache—Methotrexate—lymphatic system cancer	0.000137	0.00103	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—lymphatic system cancer	0.00013	0.00098	CcSEcCtD
